EML4-ALK is an oncogenic fusion present in ~5% lung adenocarcinomas. However, distinct EML4-ALK variants differ in the length of the EML4 microtubule-associated protein encoded within the fusion and are associated with a poorly understood variability in disease progression and therapeutic response. Here, we show that EML4-ALK variant 3, which is linked to accelerated metastatic spread and worse patient outcome, causes microtubule stabilization, formation of extended cytoplasmic protrusions, loss of cell polarity and increased cell migration. Strikingly, this is dependent upon the NEK9 kinase that interacts with the Nterminal region of EML4. Overexpression of wild-type EML4, as well as constitutive activation of NEK9, also perturbs cell morphology and accelerates cell migration in a manner that requires the downstream kinase NEK7 but not ALK activity. Moreover, elevated NEK9 is associated in patients with EML4-ALK V3 expression, as well as reduced progression-free and overall survival. Hence, we propose that EML4-ALK V3 promotes microtubule stabilization through recruitment of NEK9 and NEK7 to increase cell migration and that this represents a novel actionable pathway that drives disease progression in lung cancer.
INTRODUCTION
The EML4-ALK translocation is an oncogenic driver in a subset of lung cancers that results from an inversion on the short arm of chromosome 2 fusing an N-terminal fragment of the echinoderm microtubule-associated protein-like 4, EML4 1, 2 , to the C-terminal tyrosine kinase domain of the anaplastic lymphoma kinase, ALK. The fusion was first identified in non-smallcell lung cancer (NSCLC), where it is present in approximately 5% of cases, but has since been identified in other tumour types, including breast and colorectal cancers 3, 4, 5 . The majority of EML4-ALK lung cancers, which are predominantly adenocarcinomas, respond remarkably well to catalytic inhibitors of the ALK tyrosine kinase, such as crizotinib. However, this approach is not curative as acquired resistance to ALK inhibitors is inevitable due to either secondary mutations in the ALK tyrosine kinase domain or off-target alterations that switch dependence to other signalling pathways 6, 7, 8, 9, 10, 11 . Consequently, effective therapies capable of selectively targeting ALK inhibitor resistant lung cancers are warranted.
It is also now clear that not all EML4-ALK patients respond well to ALK inhibitor therapy in the first place 12 . One potential explanation for this is the presence of alternative EML4-ALK variants that arise from distinct breakpoints 13, 14 . All fusions encode the full C-terminal catalytic domain of the ALK kinase and an N-terminal oligomerization domain from the EML4 protein that promotes autophosphorylation. However, alternative breakpoints in the EML4 gene lead to variable amounts of the EML4 protein being present in the fusions. The N-terminal oligomerization domain of EML4 has been shown by X-ray crystallography to form trimers 15 .
This sequence is followed by an unstructured region of approximately 150 residues rich in serine, threonine and basic residues. Based on crystallographic analysis of the related EML1 protein, the ~600 residue C-terminal region folds into a tandem pair of atypical β-propellers termed the TAPE domain 16 . Structure-function studies have shown that while the C-terminal TAPE domain binds to α/β-tubulin heterodimers, it is the N-terminal domain (NTD) encompassing the trimerization motif and unstructured region that promotes binding to polymerized microtubules 15, 16 .
While all EML4-ALK fusion proteins have the trimerization motif, the distinct breakpoints mean that the different variants encode more or less of the unstructured and TAPE domains.
For example, the longer variants, 1 and 2, encode the unstructured domain and a partial fragment of the TAPE domain, while the shorter variants, 3a, 3b and 5, have none of the TAPE domain. Interestingly, the presence of a TAPE domain fragment renders the fusion protein unstable and dependent on the HSP90 chaperone for expression 16, 17 . Indeed, binding to HSP90 may interfere with microtubule association as these longer variants localise poorly to the microtubule network despite containing the microtubule-binding region 15 . In theory, this identifies an alternative therapeutic approach for patients with the longer variants through use of HSP90 inhibitors, although to date clinical trials of HSP90 inhibitors have not shown efficacy in ALK-positive patients with these variants 18, 19, 20 . Moreover, HSP90 inhibitors would not be useful in patients with EML4-ALK V3a, V3b or V5 as these fusion proteins are not dependent upon HSP90 for their expression. Furthermore, patients with V3a and V3b respond less well to ALK inhibitor treatment suggesting additional tumorigenic mechanisms that may be independent of ALK kinase activity 12 . This is important as, although V5 is rare, V3a and V3b represent up to 50% of EML4-ALK fusions in NSCLC 8, 12, 14, 21, 22 .
Wild-type EML proteins have been found to interact with members of the human NEK kinase family 23 . The human genome encodes eleven NEKs, named Nek1 to Nek11, many of which exhibit cell cycle-dependent activity and have functions in microtubule organization 24, 25, 26 .
NEK9, NEK6 and NEK7 are activated in mitosis and act in concert to regulate mitotic spindle assembly with NEK9 upstream of NEK6 and NEK7 27 . NEK6 and NEK7 are the shortest of the NEKs consisting solely of a kinase domain with a short N-terminal extension. Moreover, they are closely related being ~85% identical within their catalytic domains. In contrast, NEK9 is one of the longest NEKs, consisting of an N-terminal catalytic domain (residues 52-308)
followed by a C-terminal regulatory region (residues 309-979). Within this C-terminal region is an RCC1 (regulator of chromatin condensation 1)-like domain (residues 347-726) predicted to fold into a seven-bladed β-propeller. Biochemical studies indicate that deletion of the RCC1like domain causes constitutive activation of NEK9, indicating that this acts as an autoinhibitory domain 28 . This domain is followed by a C-terminal tail that contains a coiled-coil motif (residues 891-939) that promotes NEK9 dimerization 28 . NEK9 directly interacts with NEK7, and presumably NEK6, through a sequence that lies between the RCC1-like domain and coiled-coil 29 . NEK9 stimulates NEK6 and NEK7 kinase activity by multiple mechanisms, including activation loop phosphorylation, dimerization-induced autophosphorylation, and allosteric binding-induced reorganization of catalytic site residues 29, 30, 31 .
Here, we demonstrate that expression of not only activated NEK9 and NEK7 kinases but also full-length EML4 and the short EML4-ALK variants that bind microtubules (V3 and V5) alters cell morphology, disturbs cell polarity and promotes cell migration. These changes are not seen in cells expressing the longer variants (V1 and V2) that do not bind microtubules.
Moreover, our data reveal interaction between the EML4 NTD and NEK9, and suggest a model in which the EML4-ALK V3 and V5 proteins stabilise microtubules and perturb cell behaviour through recruitment of NEK9 and NEK7. Finally, we show that EML4-ALK lung cancer patients exhibit a significant correlation between expression of V3/V5 and high levels of NEK9 protein, and that elevated NEK9 expression is also associated with worse progression-free and overall survival raising the prospect of novel therapeutic approaches.
RESULTS

Constitutively active NEK9 leads to microtubule-dependent changes in interphase cell morphology
We initially set out to explore the functional consequences of untimely activation of NEK9 in interphase cells. For this, an inducible system was established in which expression of myctagged wild-type NEK9, a full-length kinase-inactive mutant (K81M), and a constitutively- S1D ). Although the mechanism for microtubule stabilization remains to be determined, we found that inhibition of the microtubule-based kinesin motor Eg5 with STLC also blocked this morphological change ( Fig. 1F ), in line with recent reports that Eg5 promotes microtubule stabilization in post-mitotic neurons 34 . Hence, activation of NEK9 leads to a microtubuledependent change in interphase cell morphology characterised by formation of elongated cytoplasmic protrusions that contain both actin and stabilised microtubules.
Activated NEK9 perturbs interphase cell polarity and stimulates cell migration
The morphological changes observed upon expression of activated NEK9 was characteristic of that seen in migrating cells. To test whether activated NEK9 also altered cell migration, the rate of closure of a scratch wound was measured. This revealed that cells induced to express the activated NEK9 closed the wound more quickly than cells containing an empty vector treated with doxycycline or cells containing the activated NEK9 construct but without induction ( Fig. 2A, B) . Surprisingly, this was not due to increased persistence in directional migration as these cells migrated with reduced straightness compared to control cells ( Fig. 2C ). Indeed, cells at the wound edge failed to orient either their Golgi network or their centrosomes towards the wound edge in the presence of activated NEK9 suggestive of loss of cell polarity ( Fig. 2D-F ). Isolated cells also exhibited disruption of the Golgi network that was dispersed over a larger area in cells expressing activated NEK9 (Fig. 2G, H) . Individual cell tracking experiments confirmed a significant increase in the velocity of migration as well the distance travelled in isolated cells induced to express activated NEK9 ( Fig. 2I-K ). Furthermore, there was a decrease in the straightness of migration in isolated cells in the presence of activated NEK9 consistent with more frequent changes in direction of migration ( Fig. 2L ). The wide variance in the comparator groups likely reflects the stochastic nature of migration of isolated cells in culture that may be influenced by factors such as cell cycle stage and cell density.
Finally, continuous monitoring of cell migration using a real-time transwell migration assay (xCELLigence Real Time Cell Assay) not only provided additional evidence that induction of activated NEK9 led to a significant increase in cell migration but also demonstrated that this was evident at 10 hours after induction and is therefore is not a result of increased proliferation ( Fig. 2M, N) . Taken together, these data demonstrate that expression of activated NEK9 not only leads to a change in interphase cell morphology but also perturbs cell polarity and enhances cell migration.
NEK9-induced changes in cell morphology and migration are dependent on NEK7
A major function of NEK9 activity in mitosis is to activate NEK6 and NEK7 24 . This is thought to occur via both phosphorylation of activation loop residues and allosteric binding 30, 31 . Indeed, biochemical and structural studies have revealed direct interaction between residues 810-828 of NEK9 and a groove on the C-terminal lobe of the NEK7 catalytic domain 29 . To determine whether the change in interphase cell morphology and migration induced by activated NEK9 is dependent on NEK6 or NEK7, cells expressing activated NEK9 were depleted of NEK6 or NEK7 (Supp. Fig. S2A ). Quantitative imaging revealed that, in contrast to mock-or NEK6depleted cells that still exhibited extended cytoplasmic protrusions upon induction of activated NEK9, depletion of NEK7 prevented formation of these protrusions ( Fig. 3A; and Supp. Fig.   S2B ). This suggested that this phenotype was dependent upon the untimely activation of NEK7 by NEK9. To confirm this hypothesis, we made use of a constitutively active mutant version of NEK7. Previous studies had revealed that, in the absence of NEK9, NEK7 adopts an auto-inhibited conformation in which the side-chain of Tyrosine-97 blocks the active site and that mutation of this residue to alanine relieves this inhibition 31 . Strikingly, transient expression of the activated NEK7-Y97A mutant, but not wild-type NEK7, caused generation of similar elongated cytoplasmic protrusions in U2OS cells ( Fig. 3B, C) . Consistent with the 7 lack of effect of NEK6 depletion, expression of the equivalent activated NEK6-Y108A mutant did not cause formation of cytoplasmic protrusions but rather caused cells to become more rounded. Real-time transwell assays indicated that the increase in cell migration induced by activated NEK9 was also dependent on NEK7 but not NEK6 and, as it was detected after 10 hours, unlikely to be explained by reduced proliferation (Fig. 3D , E; and Supp. Figs. S2C, D).
To further address the role of NEK7 in this pathway, we established HeLa cell lines in which YFP tagged wild-type, catalytically-inactive (D179N) and constitutively-active (Y97A) versions of NEK7 were expressed under the control of a tetracycline inducible promoter ( Fig. S3 ).
Consistent with transient expression, inducible expression of activated NEK7 but not wild-type or kinase-inactive NEK7 resulted in the formation of microtubule rich cytoplasmic protrusions in interphase ( Fig. 3F, G) . Analysis of the localization of the activated NEK7 protein by SRRF microscopy revealed substantial co-localisation with microtubules in the cytoplasmic protrusions ( Fig. 3H ). Interestingly, these protrusions formed upon expression of activated NEK7 were lost upon depletion of NEK9 suggesting a more complex relationship than NEK9 simply acting upstream to enhance NEK7 catalytic activity ( Fig. 3I ). Together, these data indicate that the microtubule-dependent alteration of cell morphology and increased rate of migration that occur upon activation of NEK9 is dependent on NEK7, but equally that similar changes induced upon activation of NEK7 are dependent on NEK9.
EML4 interacts with NEK9 and promotes cell migration
To determine the mechanism through which the NEK9-NEK7 pathway may cause this change in cell morphology and migration, myc-tagged wild-type NEK9 was immunoprecipitated from the stable cell line and immune complexes analysed by mass spectrometry. Intriguingly, this identified not only tubulin but also the microtubule-associated protein, EML4, as a NEK9 binding partner (Supp. Fig. S4A -C). Previous large-scale proteomic mapping had identified EML2, EML3 and EML4 as potential binding partners of NEK6 23 , while we have found that both EML3 and EML4 can be phosphorylated in vitro by NEK6 and NEK7 (R.A., L.O., M.W.R., R.B., A.M.F., manuscript in preparation). Western blotting of immunoprecipitates prepared with antibodies against either NEK9 or EML4 confirmed interaction between endogenous EML4 and NEK9 in extracts prepared from asynchronous U2OS cells ( Fig. 4A ).
Moreover, YFP-EML4 was found to co-precipitate equally well with the activated NEK9-ΔRCC1 mutant as wild-type NEK9 (Fig. 4B ). NEK9 is also known to bind directly through its C-terminal region to NEK7 and NEK6, an interaction that is normally blocked in interphase by competitive interaction with the LC-8 adaptor protein 29, 35 . Removal of the RCC1 domain relieves the auto-inhibited conformation and leads to activation of NEK9 28 . This in turn enables autophosphorylation at Ser-944, which displaces LC-8 and allows interaction with NEK7 and NEK6 35 . Hence, we propose that activated NEK9 can potentially interact simultaneously with both EML4 and NEK7.
To investigate whether the microtubule-dependent changes in cell morphology that result from expression of activated NEK9 and NEK7 may relate to its interaction with EML4, U2OS stable cell lines were generated that expressed YFP alone or YFP-EML4. These cell lines 
EML4 recruits NEK9 and NEK7 to microtubules
To understand how NEK9 and NEK7 act downstream of EML4 to induce alterations in cell morphology and migration, we first examined which region of the EML4 protein may be responsible for interaction with NEK9. Co-immunoprecipitation experiments revealed that endogenous NEK9 could interact not only with full-length EML4 but also both the isolated NTD and TAPE domains ( Fig. 5A ). On the other hand, it did not interact with a shorter fragment of the NTD that only encompassed the trimerization domain. As NEK9 could interact with the microtubule-binding EML4 NTD, we hypothesized that EML4 may promote recruitment of NEK9 and NEK7 to the microtubule cytoskeleton. To test this hypothesis, we examined the localization of endogenous NEK9 in cells expressing different EML4 constructs.
In cells expressing the TAPE domain, endogenous NEK9 was mainly distributed in the cytoplasm with only faint detection on microtubules, whereas in cells expressing the NTD, NEK9 exhibited strong recruitment to microtubules ( Fig. 5B , C; and Supp. Fig. S6A ). Further studies using the stable HeLa:YFP-NEK7 cell line revealed that YFP-NEK7 was recruited to microtubules upon transfection of Flag-tagged EML4 NTD, but not the TAPE domain ( Fig. 5D , E; and Supp. Fig. S6B ). Together, these data suggest a model in which the EML4 NTD recruits both NEK9 and NEK7 to microtubules. This explains not only how EML4 can act upstream of NEK9 and NEK7, but also why the NEK9 protein is required for activated NEK7
to promote microtubule-dependent changes in cell morphology and migration.
EML4-ALK variants that localise to microtubules induce altered cell morphology, polarity and migration
Considering their importance in cancer biology, we were intrigued to know whether EML4-ALK fusion proteins might also alter cell morphology and migration. To explore this possibility, we generated U2OS cell lines with stable expression of the ALK kinase domain alone or four of the different EML4-ALK variants ( Fig. 6A ). These included the longer variants, V1 and V2, which encode unstable proteins that do not localise to microtubules, and the shorter variants, V3a and V5, which encode stable proteins that localise to microtubules 15, 16 . Strikingly, microscopic analysis revealed that those cells in which the variant localised to interphase microtubules (V3a and V5) formed extended cytoplasmic protrusions, whereas those cells in which the variant did not localise to the microtubules (V1 and V2) did not ( Fig. 6B-D ).
Furthermore, both individual cell tracking and real-time transwell assays revealed that expression of variants 3a and 5 stimulated cell migration with significant increases in distance and velocity and decreased straightness, whereas expression of V1 and V2 did not ( Fig. 6E -I). To assess the consequences of these variants on cell polarity, Golgi orientation was measured in a wound-healing assay with U2OS cells expressing either EML4-ALK V1 or V3a.
The percentage of cells in which the Golgi was oriented towards the wound was lower in cells expressing V1 (75%) than in parental U2OS cells, potentially due to a modest effect on microtubule organization. However, there was a significant reduction in Golgi orientation in cells expressing V3a (58%) as compared to V1 ( Fig. 6J ). We also analysed centrosome orientation and found that cells expressing V3a had substantially reduced ability to orient their centrosomes towards the wound edge, while single cell tracking of cells at the wound edge revealed a significant decrease in straightness of migration ( Fig. 6K & L) . Furthermore, the area occupied by the Golgi network was significantly greater in isolated cells expressing V3a as compared to ALK alone or V1 ( Fig. 6M & N) . Hence, expression of the short EML4-ALK variants that localize to microtubules lead to altered morphology, reduced polarity and enhanced migration as compared to cells expressing the longer EML4-ALK variants that do not localise to microtubules.
Changes mediated by EML4-ALK V3 depend on NEK9 and NEK7 but not ALK activity
To determine whether the changes observed in cell morphology and migration induced by EML4-ALK V3 required catalytic activity of the ALK tyrosine kinase, we first generated U2OS stable cell lines with catalytically-inactive (D1270N) versions of EML4-ALK V1 and V3. This revealed that cells expressing the inactive mutant proteins had similar length cytoplasmic protrusions as those seen in cells expressing the wild-type proteins (Fig. 7A ). Second, we determined the consequences on cell migration of treatment with the ALK inhibitor, crizotinib.
This did not alter the rate of migration of U2OS cells expressing EML4-ALK V3a despite preventing ALK-dependent signalling in these cells as expected ( Fig. 7B , C; and Supp. Fig.   S7A ). Hence, we conclude that the altered morphology and enhanced migration of cells expressing EML4-ALK V3 does not require ALK activity.
As the EML4-ALK variants all contain the EML4-NTD that in isolation can interact with NEK9, we tested whether these oncogenic fusion variants also bind NEK9. Surprisingly, coimmunoprecipitation experiments showed that endogenous NEK9 interacts with EML4-ALK V3a and V5, but not with V1 or the ALK domain alone (Fig. 7D ). The explanation for this might be that, like microtubule binding, interaction with NEK9 is prevented by NTD misfolding or chaperone association of the large variants that possess a partial TAPE domain.
Consistent with this and previous studies, real-time transwell migration assays revealed that depletion of NEK9 and NEK7 significantly reduced the migration of cells expressing EML4-ALK V3a or V5 ( Fig. 7E-H) . As wild-type EML4 can promote microtubule stabilization 36 , we wished to determine whether expression of EML4-ALK V3a caused a similar increase in microtubule stabilisation to that observed in cells expressing activated NEK9. Both Western blot analysis of acetylated tubulin abundance and measurement of the rate of nocodazoleinduced microtubule depolymerisation in live cells using the SiR-tubulin probe confirmed that cells expressing EML4-ALK V3a had increased microtubule stability as compared to cells expressed EML4-ALK V1 ( Fig. 7I , J; and Supp. Fig. S7B ). We therefore conclude that expression of EML4-ALK V3a but not V1 leads to NEK9 and NEK7-dependent alterations in cell morphology and migration, and to enhanced stabilization of microtubules.
EML4-ALK V3 patient cells exhibit NEK9 and NEK7-dependent alteration of cell morphology and migration
To determine whether the altered cell morphology and migration observed in stable cell lines Individual cell tracking experiments indicated that depletion of NEK7 or NEK9 reduced the distance and increased the straightness of migration in H2228, but not H3122, cells (Fig 8J, K; and Supp. Fig. S8A -C). Again consistent with data in stable cell lines, the elongated protrusions present in H2228 cells were not affected by treatment with the ALK inhibitor crizotinib, whereas they were reduced upon depolymerisation of microtubules with nocodazole ( Fig. 8L, M) . Importantly, to confirm that the differences observed in H2228 cells compared to H3122 cells were caused by the different EML4-ALK variant expressed, we first transfected H3122 cells with YFP-EML4-ALK-V3a. This caused a significant increase in the length of interphase cytoplasmic protrusions in H3122 cells ( Fig 8N) . Second, we depleted EML4-ALK V3 from H2228 cells and found that this led to a significant reduction in cytoplasmic protrusion length ( Fig. 8O , P). Together, these data provide persuasive evidence that the different behaviour of these established NSCLC cells results from the different EML4-ALK fusion variant that they express.
Lung cancer patients with EML-ALK V3 exhibit upregulation of NEK9
Results in established cell lines suggest that the more aggressive properties associated with EML4-ALK V3 as compared to V1 may at least in part be caused by a NEK9-dependent pathway that promotes cell migration. This hypothesis would require NEK9 protein to be expressed in EML4-ALK V3 tumours. To test this, we used immunohistochemistry to examine NEK9 expression in a cohort of primary tumours from patients with ALK-positive stage IV advanced lung adenocarcinoma. Remarkably, this revealed that while the majority of tumours expressing V1, V2 (or others) had low levels of NEK9 expression (64%, n=25), the majority of tumours expressing V3 or V5 had medium or high levels of NEK9 expression (91%, n=22; Fig. 9A, B ). Intriguingly, patients with medium or high NEK9 expression also exhibited worse overall (p=0.083) and progression-free (p=0.027) survival than patients with low levels of NEK9 expression ( Fig. 9C, D) . Assessment of clinicopathological features revealed that, although there was no association with gender, age or smoking history, EML4-ALK patients with low NEK9 expression had on average undergone more rounds of previous treatment suggestive of more prolonged and potentially less aggressive disease than those with moderate or high NEK9 expression ( Supplementary Tables 1 & 2) . Clearly, further work will be required to define the molecular events that underpin the apparent link between elevated NEK9 and both EML4-ALK variant expression and patient survival. However, these findings raise the exciting possibility not only that these NSCLCs could be amenable to treatments that target NEK9 or NEK7, but also that this pathway represents an important mechanism through which variants that bind microtubules accelerate lung cancer progression ( Fig. 9E ).
DISCUSSION
A better understanding of the processes that drive progression and metastatic dissemination of EML4-ALK tumours is urgently required as this will identify opportunities for development of new therapeutic approaches to treat ALK inhibitor-resistant NSCLC. Here, we show that the short EML4-ALK variants, including the common V3 and less common V5, promote microtubule-dependent changes in cell morphology and enhance cell migration in a manner that could promote dysplastic development and metastasis. EML4-ALK V3 is associated with poor response to ALK inhibitors suggesting additional oncogenic mechanisms that are independent of ALK tyrosine kinase activity 12 . Indeed, we found that these changes induced by EML4-ALK V3 were not dependent on ALK activity. Experimentally, these short variants retain the capacity to bind microtubules. This is in contrast to the longer variants, V1 and V2, that possess destabilizing fragments of the EML4 TAPE domain and rely on the HSP90 chaperone for expression 16 . We speculate that either protein misfolding or chaperone interaction blocks the ability of the longer variants to associate with and regulate microtubules. We also show that the altered cell morphology and increased migration induced by these short EML4-ALK variants are dependent on the NEK9-NEK7 kinase module. Hence, these data not only reveal a novel mechanism through which EML4-ALK variants can promote cancer progression, but also identify a new targeted approach through which patients with these oncogenic fusions could be treated.
NEK9 is required for assembly of the microtubule-based mitotic spindle. This is consistent with the kinase achieving maximal activity in mitosis following phosphorylation by the CDK1 and PLK1 mitotic kinases 24 . These phosphorylation events cause release of an auto-inhibited state that relies on the presence of an internal RCC1-like inhibitory domain 28 . Upon inducible expression of an activated mutant lacking this domain, we observed striking alterations in interphase cell morphology and significantly enhanced cell migration. The mitotic functions of NEK9 are executed in part through phosphorylation of the microtubule nucleation adaptor protein, NEDD1/GCP-WD, and in part through activation of two other members of the NEK family, NEK6 and NEK7 28, 30, 37, 38, 39 . Interestingly, we found that depletion of NEK7, but not NEK6, prevented the altered cell morphology and enhanced migration observed in interphase cells arguing that activated NEK9 promotes these phenotypes through activation of NEK7.
Indeed, similar phenotypes were generated by expression of a constitutively active NEK7, but not NEK6, kinase. These findings are consistent with growing evidence that NEK7 has microtubule-associated functions in interphase cells, with endogenous NEK7 localizing to the centrosome and depletion interfering with interphase microtubule dynamics, the centrosome duplication cycle and ciliogenesis 40, 41, 42, 43, 44 . Of particular interest to our findings, a kinasedependent role was recently described for NEK7 in stimulating dendrite growth in post-mitotic neurons. This resulted from phosphorylation by NEK7 of the kinesin motor protein Eg5, which in turn led to stabilization of microtubules 34 . Supporting a similar mechanism of action in cancer cells, we found that Eg5 was required for the altered cell morphology induced by activated NEK9. As EML4 is highly expressed in neurons, we therefore speculate that modulation of microtubule organization leading to altered cell morphology and migration may represent the normal physiological role for the EML4-NEK9-NEK7 pathway identified here.
However, NEK7 can phosphorylate other motor proteins to control microtubule organization, and interacts with additional regulators of both the microtubule and actin networks, offering alternative mechanisms through which these kinases can influence cell movement 45, 46 . consisting of an NTD that encompasses a trimerization motif and basic region that binds microtubules, and a C-terminal TAPE domain that binds tubulin heterodimers 15, 16 . The possibility that EMLs may be interacting partners of NEKs was first raised by a proteomic study that identified association of NEK6 not only with NEK7 and NEK9, but also EML2, EML3 and EML4 23 . We identified EML4, as well as tubulin, in a mass spectrometry analysis for NEK9 binding partners, while interaction of endogenous EML4 and NEK9 was confirmed by Western blotting. Co-immunoprecipitation studies revealed that NEK9 can bind to the isolated NTD of EML4, as well as to the EML4-ALK V3 and V5 proteins. Interestingly, it did not bind to EML4-ALK V1 despite this variant encoding the complete NTD. Again this suggests that misfolding or binding of chaperones prevents interaction with NEK9. Further studies revealed that the EML4 NTD was capable of recruiting both NEK9 and NEK7 to microtubules. Firstly, this suggests that binding of the NTD to microtubules and NEK9 are not mutually exclusive. Secondly, it allows us to propose that EML4 recruits NEK9 to microtubules and that, in turn, NEK9 recruits NEK7. Assuming that the morphological consequences that we observe are dependent upon phosphorylation of microtubuleassociated substrates downstream of NEK7, this also explains why NEK9 is required even in the presence of an activated NEK7 mutant. However, although we have shown that expression of activated NEK9 and EML4-ALK V3 leads to stabilization of microtubules, further work is required to establish the detailed mechanisms through which this pathway alters microtubule dynamics to change cell shape, polarity and migration.
Of major clinical significance is the fact that EML4-ALK fusion proteins act as oncogenic drivers in ~5% of NSCLC patients 4 . Unscheduled activation of the ALK tyrosine kinase is primarily responsible for driving tumorigenesis as demonstrated by the fact that ALK inhibitors block transformation. ALK inhibitors have revolutionized survival outcomes in EML4-ALK NSCLC, however resistance is inevitable emerging through point mutations in the catalytic domain as well as through activation of bypass signalling pathways 48, 49 . Alternative targeted therapies would therefore be highly attractive and, in the case of the longer variants, HSP90
inhibitors could provide an option. The longer variants are unstable proteins as a result of expressing an incomplete fragment of the highly structured TAPE domain. In the absence of the HSP90 chaperone they are rapidly degraded by the proteasome leading to loss of downstream proliferative signalling 16 . HSP90 inhibitors have been tested in EML4-ALKpositive patients although to date clinical trials have yet to prove their efficacy 19, 50 . The short variants though are not dependent on HSP90 for their expression and so HSP90 inhibitor treatment is unlikely to be effective. Moreover, EML4-ALK V3 tumours are insensitive to ALK inhibitors in the first place emphasizing the need for alternative treatments for these particular patients 12 . Demonstration that the downstream consequences on cell morphology and migration induced by these short variants is dependent on NEK9 and NEK7, but not ALK activity, raises the tantalizing prospect that inhibitors of this pathway would be beneficial in EML4-ALK V3 cancers where metastasis and ALK inhibitor resistance underpin lethality 22 .
Although we have no evidence that inhibiting this pathway promotes cytotoxicity, the ability to block migration and invasion with so-called 'migrastatics' offers huge potential benefits in slowing disease progression in patients with solid cancers 51 .
The significant correlation in patient samples between elevated NEK9 expression and EML4-ALK V3 is particularly intriguing as it implicates this pathway in the high metastatic potential of these tumours 22, 52 . However, although the association of elevated NEK9 with V3 and V5 was significant, expression does not necessarily reflect activation and it will be important in the future to assess the catalytic activity of NEK9 and NEK7 in these tumours. Moreover, we cannot rule out that tumour cells with this variant exert positive selection for high expression of NEK9 either due to its role as a downstream target or as a result of their increased aggressiveness. Nevertheless, the reduced progression-free and overall survival of patients with increased NEK9 expression potentially explains the poor response of these patients to ALK-based therapies, despite the fact that the different EML4-ALK variants bind ALK inhibitors with similar affinity 17 . This also adds further evidence that NEK9 may be an important prognostic factor for EML4-ALK lung cancers and supports the hypothesis that targeting NEK9 or NEK7 could be beneficial in patients with EML4-ALK V3.
Finally, it is interesting to note that EML proteins are involved in other oncogenic fusions, including the EML1-ABL1 fusion found in T-cell acute lymphoblastic leukaemia (ALL) 53 .
Whether these also localise to microtubules and alter cell morphology and migration in a manner that is dependent on the microtubule network and the NEK9-NEK7 kinase module will be important to examine. Standard treatments for many cancers, including NSCLC and ALL, often involve microtubule poisons, such as vinca alkaloids or taxanes. Hence, it will also be worthwhile to explore the possibility that EML4-ALK variant status affects response to these drugs, and test whether there could be patient benefit in combining microtubule poisons with targeted agents against ALK, HSP90 or indeed NEK9 or NEK7.
MATERIALS & METHODS
Plasmid construction and mutagenesis
Full-length EML4 cDNA was isolated by PCR from human cDNA (Clontech) and subcloned into a version of pcDNA3 or pcDNA3.1-hygro (Invitrogen) providing N-terminal YFP-or Flagtags. YFP-tagged EML4-ALK variants and fragments of EML4, and Flag-tagged NEK6 and NEK7 constructs were generated as previously described 15, 16, 54 
Preparation of cell extracts, SDS-PAGE and Western blotting
Cells were lysed in RIPA lysis buffer ( and Hss178451 On-Target Plus duplexes (Dharmacon); siRNA duplexes for NEK6 and NEK7
were as previously described 54, 20 .
Immunoprecipitation, kinase assay and mass spectrometry
Cells were harvested by incubation with 1x PBS+0.5 mM EDTA and pelleted by centrifugation prior to being lysed in NEB lysis buffer 55 
Individual Cell Tracking Assays
To allow automated detection of individual cells for tracking analysis cells were transfected with YFP alone and subjected to time lapse imaging as appropriate. Individual cell tracking was then analysed using Imaris (Bitplane). Fluorescent cells were identified using the Imaris spots function and subsequently the Imaris TrackLineage algorithm was used to identify movements or tracks of these cells through the entire time period and thus provide numerical values for parameters such as speed and distance.
Live-cell microtubule stability assays
For live cell microtubule stability assays cells were grown in µ-well 8 well chamber slides (ibidi). Cells were incubated with 25 nM SiR-Tubulin (Cytoskeleton Inc.) for 4 h prior to imaging, 10 images were captured prior to addition of nocodazole and the drug was then added and a further 15 images were captured. Z stacks comprising of approximately 10 0.5
µm sections were captured every 30 s for 7 mins. Images were cropped to single cells and deconvolved prior to analysis in Matlab.
Cell migration assays
For scratch-wound assays, cells were grown to 95% confluency in 6 well dishes before a pipette tip was used to scrape a 0.5 -1 µm line across the width of the well. Cells were Measurements were taken every 15 mins for 48 h.
Statistical analysis
All quantitative data represent means and SD of at least three independent experiments.
Statistical analyses were performed using a one-tailed unpaired Student's t test assuming unequal variance, a one-way analysis of variance followed by post hoc testing or a χ 2 test, as appropriate. p-values represent *, p< 0.05; **, p< 0.01; ***, p< 0.001. n.s., non-significant.
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